Acres Bruce, Bonnefoy Jean-Yves
Transgene SA, Strasbourg, Cedex 67082, France.
Expert Rev Vaccines. 2008 Sep;7(7):889-93. doi: 10.1586/14760584.7.7.889.
Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patient's own immune system generating an effective anti-tumor immune response. The advantage of this over therapy with monoclonal antibodies for the treatment of cancer is that multiple antigenic epitopes can be involved and the immune system is able to adapt to the most effective antigenic specificity for tumor growth control and rejection. In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens.
肿瘤相关抗原（TAAs）已被制成疫苗，这些疫苗与佐剂、细胞因子或其他增强免疫反应的策略相结合，目前正处于临床开发阶段。使用这些疫苗已产生了针对TAAs的体液免疫和细胞免疫反应。这种方法依赖于患者自身的免疫系统产生有效的抗肿瘤免疫反应。与使用单克隆抗体治疗癌症相比，这种方法的优势在于可以涉及多个抗原表位，并且免疫系统能够适应最有效的抗原特异性以控制肿瘤生长和排斥肿瘤。在本文中，我们描述了痘苗病毒，特别是安卡拉改良痘苗病毒（MVA）在体内表达TAAs并刺激对癌症抗原产生有效免疫反应的临床应用。
